FrancophonIA/ELRC3.0 huggingface dataset:
English: Some clinical findings also support a possible interaction between lamivudine and cladribine.
Slovenian: Tudi nekateri klinični izsledki potrjujejo možno medsebojno delovanje med lamivudinom in kladribinom, zato sočasna uporaba zdravila DUTREBIS in kladribina ni priporočljiva (glejte poglavje 4.4).
English: /sulfamethoxazole is necessary, unless the patient has renal impairment (see section 4.2).
Slovenian: Odmerka zdravila DUTREBIS ali kombinacije trimetoprim/sulfametoksazol ni treba prilagoditi, če bolnik nima okvare ledvic (glejte poglavje 4.2).
English: Depression, including suicidal thoughts and behaviours, has been reported in some patients taking raltegravir (one of the medicines in
Slovenian: Pri nekaterih bolnikih, ki so jemali raltegravir (ena od zdravilnih učinkovin v zdravilu DUTREBIS), so poročali o depresiji, vključno s samomorilnimi mislimi in obnašanjem, še posebej pri bolnikih, ki so že kdaj prej
English: No dose adjustment required for DUTREBIS.
Slovenian: Odmerka zdravila DUTREBIS ni treba prilagoditi.
English: Musculoskeletal common arthralgia, muscle disorders uncommon arthritis, back pain, flank pain, musculoskeletal pain, myalgia, neck pain, osteopenia, pain in extremity, tendonitis, rhabdomyolysis uncommon renal failure, nephritis, nephrolithiasis, nocturia, renal cyst, renal uncommon erectile dysfunction, gynaecomastia, menopausal symptoms uncommon chest discomfort, chills, face oedema, fat tissue increased, feeling jittery, submandibular mass, oedema peripheral, pain
Slovenian: Bolezni jeter, žolčnika in žolčevodov občasni hepatitis, steatoza jeter, alkoholni hepatitis, odpoved jeter akne, akneiformen dermatitis, suha koža, eritem, upadlost obraza, hiperhidroza, lipoatrofija, pridobljena lipodistrofija, lipohipertrofija, nočno znojenje, prurigo, pruritis, generaliziran pruritis, makularen izpuščaj, makulo-papulozen izpuščaj, srbeč izpuščaj, poškodbe kože, urtikarija, kseroderma, Stevens-Johnsonov sindrom, izpuščaj z eozinofilijo in sistemskimi simptomi kot posledica zdravljenja z artritis, bolečina v hrbtu, bolečina v ledvenem predelu, mišičnoskeletna bolečina, mialgija, bolečina v vratu, osteopenija, bolečina v odpoved ledvic, nefritis, nefrolitiaza, nokturija, ledvična cista, okvara erektilna disfunkcija, ginekomastija, menopavzalni simptomi astenija, utrujenost, splošno slabo počutje, zvišana telesna nelagodje v prsih, mrzlica, edem obraza, povečanje maščobnega tkiva, občutek živčnosti, submandibularna tvorba, periferni edemi,
English: Vistor hf.
Slovenian: FK lamivudina ↔
English: • When your supply of DUTREBIS starts to run low, get more from your doctor or pharmacy.
Slovenian: • Ko vam začne tablet DUTREBIS zmanjkovati, si pravočasno priskrbite nove.
English: • chest discomfort; chills; swelling of face; feeling jittery; lump in the neck; swelling of
Slovenian: • nelagodje v prsih, mrzlica, oteklost obraza, živčnost, bula na vratu, oteklost dlani, gležnjev ali stopal, bolečine
English: No dosage adjustment of DUTREBIS or trimethoprim
Slovenian: Odmerka zdravila DUTREBIS ali midazolama ni treba prilagoditi.
English: No dosage adjustment for DUTREBIS is required for patients with mild to moderate hepatic impairment.
Slovenian: Bolnikom z blago do zmerno okvaro jeter odmerka zdravila DUTREBIS ni treba prilagoditi.
English: No specific signs or symptoms have been identified following such overdose.
Slovenian: Po takšnem prevelikim odmerjanjem niso opazili
English: Anti-retroviral Pregnancy Registry
Slovenian: Seznam neželenih učinkov v preglednici
English: Interaction not studied cladribine /raltegravir
Slovenian: Medsebojno delovanje ni trimetoprim/sulfametoksazol/raltegravir Medsebojno delovanje ni
English: Tel.: +420 233 010 111 dpoc_czechslovak@merck.com
Slovenian: Τηλ: + 30 210 98 97 300 dpoc_greece@merck.com
English: Considerable inter- and intra-individual variability was observed in the pharmacokinetics of raltegravir.
Slovenian: Glede na spol, raso ali indeks telesne mase (ITM) pri odraslih niso ugotovili klinično pomembnih razlik v farmakokinetiki raltegravirja.
English: H2 BLOCKERS AND PROTON PUMP INHIBITORS
Slovenian: ANTAGONISTI H2 IN ZAVIRALCI PROTONSKE ČRPALKE AUC raltegravirja ↑ 37 %
English: aluminium and magnesium hydroxide antacid /lamivudine
Slovenian: etinilestradiol norelgestromin/lamivudin
English: Elderly
Slovenian: Plodnost
English: Because the extent to which DUTREBIS may be dialyzable is unknown, dosing before a dialysis session should be avoided (see section 4.2).
Slovenian: Ker obseg izločanja zdravila DUTREBIS pri dializi ni znan, se je treba izogibati zaužitju zdravila pred dializo
English: The medicine is given once every 12 hours for at least 4 days and up to 14 days.
Slovenian: Zdravilo se daje enkrat na vsakih 12 ur najmanj štiri in največ 14 dni.
English: Xerava (eravacycline)
Slovenian: Xerava (eravaciklin)
English: Further information on Xerava can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Nadaljnje informacije o zdravilu Xerava so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: ‘Complicated' means that the infection is difficult to treat because it has spread to the abdominal space.
Slovenian: „Zapletena“ pomeni, da je okužbo težko zdraviti, ker se je razširila v trebušni prostor.
English: Therefore the European Medicines Agency decided that Xerava's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Xerava večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: Xerava (eravacycline) EMA/521584/2018
Slovenian: Xerava (eravaciklin) EMA/521584/2018
English: Xerava's safety profile was considered acceptable.
Slovenian: Varnostni profil zdravila Xerava je bil ocenjen kot sprejemljiv.
English: What measures are being taken to ensure the safe and effective use of Xerava?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Xerava?
English: The most common side effects with Xerava (which may affect up to 1 in 10 people) are thrombophlebitis (inflammation of veins caused by a blood clot), phlebitis (inflammation of a vein), nausea (feeling sick), vomiting and reactions at the site of the infusion including reddening of skin, reduced sense of touch and pain.
Slovenian: Najpogostejši neželeni učinki zdravila Xerava (ki se lahko pojavijo pri največ 1 bolniku od 10) so tromboflebitis (vnetje ven, ki ga povzroči krvni strdek), flebitis (vnetje vene), navzeja (slabost), bruhanje in reakcije na mestu infundiranja, vključno s pordelostjo kože, zmanjšanim občutkom za dotik in bolečino.
English: The dose depends on the patient's bodyweight, and may be increased if the patient is also taking a type of medicine called a ‘strong CYP3A4 inducer'.
Slovenian: Odmerek je odvisen od bolnikove telesne mase in se lahko poveča, če bolnik jemlje tudi vrsto zdravila, imenovano „močni induktor CYP3A4“.
English: This leads to death of the bacteria causing the infection.
Slovenian: Posledično odmrejo bakterije, ki povzročajo okužbo.
English: Why is Xerava authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Xerava odobreno v EU?
English: Other information about Xerava
Slovenian: Druge informacije o zdravilu Xerava
English: Tetracyclines work by binding to and blocking part of the cell machinery in bacterial cells that is involved in making proteins.
Slovenian: Tetraciklini delujejo tako, da se vežejo na del celičnega ustroja bakterijskih celic, ki je udeležen pri izdelavi beljakovin, in ga zavirajo.
English: Side effects reported with Xerava are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Xerava, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: As for all medicines, data on the use of Xerava are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Xerava stalno spremljajo.
English: What is Xerava and what is it used for?
Slovenian: Kaj je zdravilo Xerava in za kaj se uporablja?
English: An overview of Xerava and why it is authorised in the EU
Slovenian: Pregled zdravila Xerava in zakaj je odobreno v EU
English: What benefits of Xerava have been shown in studies?
Slovenian: Kakšne koristi zdravila Xerava so se pokazale v študijah?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xerava have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Xerava upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: What are the risks associated with Xerava?
Slovenian: Kakšna tveganja so povezana z zdravilom Xerava?
English: For more information about using Xerava, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Xerava glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: Xerava must not be used in patients who are hypersensitive (allergic) to any of the ingredients of the medicine or to other tetracycline antibiotics.
Slovenian: Zdravila Xerava ne smejo uporabljati bolniki, ki so preobčutljivi za (alergični na) katero koli sestavino zdravila ali druge tetraciklinske antibiotike.
English: After around a month, 87% of patients treated with Xerava were cured of their infection, compared to 89% of patients treated with ertapenem.
Slovenian: Po približno enem mesecu je bila okužba ozdravljena pri 87 % bolnikov, zdravljenih z zdravilom Xerava, v primerjavi z 89 % bolnikov, zdravljenih z ertapenemom.
English: In the first study involving 538 patients, Xerava was compared with ertapenem (another antibiotic).
Slovenian: V prvi študiji, v katero je bilo vključenih 538 bolnikov, so zdravilo Xerava primerjali z ertapenemom (drugim antibiotikom).
English: In the second study involving 499 patients, Xerava was compared with meropenem (another antibiotic).
Slovenian: V drugi študiji, v katero je bilo vključenih 499 bolnikov, so zdravilo Xerava primerjali z meropenemom (drugim antibiotikom).
English: Xerava is an antibiotic used to treat complicated intra-abdominal (belly) infections (cIAI) in adults.
Slovenian: Zdravilo Xerava je antibiotik, ki se uporablja za zdravljenje zapletenih intraabdominalnih (trebušnih) okužb pri odraslih.
English: Xerava can only be obtained with a prescription and prescribers should take into account official guidance on the use of antibiotics.
Slovenian: Predpisovanje in izdaja zdravila Xerava je le na recept, poleg tega morajo zdravniki, ki zdravilo predpisujejo, upoštevati uradne smernice za uporabo antibiotikov.
English: The active substance in Xerava, eravacycline, belongs to a group of antibiotics called tetracyclines.
Slovenian: Učinkovina v zdravilu Xerava, eravaciklin, spada v skupino antibiotikov, imenovanih tetraciklini.
English: After around a month, 92% of patients treated with Xerava and 92% of patients treated with meropenem were cured of their infection.
Slovenian: Po približno enem mesecu je bila okužba ozdravljena pri 92 % bolnikov, zdravljenih z zdravilom Xerava, in 92 % bolnikov, zdravljenih z meropenemom.
English: Xerava is as effective as alternative antibiotics in treating infections caused by various types of bacteria and produced high cure rates.
Slovenian: Zdravilo Xerava je pri zdravljenju okužb, ki jih povzročajo različne vrste bakterij, enako učinkovito kot drugi antibiotiki in je privedlo do visoke stopnje ozdravitve.
English: Xerava was shown to be as effective as alternative antibiotics in 2 main studies of adults with cIAIs.
Slovenian: Zdravilo Xerava se je izkazalo enako učinkovito kot drugi antibiotiki v dveh glavnih študijah odraslih z zapleteno okužbo v trebuhu.
English: Xerava contains the active substance eravacycline.
Slovenian: Zdravilo Xerava vsebuje učinkovino eravaciklin.
English: How is Xerava used?
Slovenian: Kako se zdravilo Xerava uporablja?
English: How does Xerava work?
Slovenian: Kako zdravilo Xerava deluje?
English: For the full list of side effects of Xerava, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Xerava, glejte navodilo za uporabo.
English: Xerava is given by infusion (drip) into a vein over one hour.
Slovenian: Zdravilo Xerava se daje kot enourna (kapalna) infuzija v veno.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Cuprymina on 23 August 2012.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Cuprymina, veljavno po vsej Evropski uniji, odobrila dne 23. avgusta 2012.
English: It must not be used in women who are known to be or may be pregnant.
Slovenian: Zdravila ne smejo uporabljati nosečnice ali ženske, ki bi lahko bile noseče.
English: The full EPAR for Cuprymina can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Cuprymina je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is a summary of the European public assessment report (EPAR) for Cuprymina.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Cuprymina.
English: Other information about Cuprymina
Slovenian: Druge informacije o zdravilu Cuprymina
English: The doctor will ensure that the risks linked to the radioactive exposure are lower than the risks from the disease itself.
Slovenian: Zdravnik bo poskrbel, da je tveganje, povezano z izpostavitvijo radioaktivnosti, manjše od bolezni same.
English: For more information about treatment with Cuprymina, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Cuprymina preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
English: What benefit has Cuprymina shown during the studies?
Slovenian: Kakšne koristi je zdravilo Cuprymina izkazalo med študijami?
English: Cuprymina is never given directly to the patient.
Slovenian: Zdravilo Cuprymina se nikoli ne daje bolniku neposredno.
English: The CHMP considered that there are no major safety concerns with regard to potential copper toxicity, since Cuprymina is used at very low doses.
Slovenian: CHMP je menil, da ni poglavitnih varnostnih zadržkov v zvezi z možnim toksičnim učinkom bakra, ker se zdravilo Cuprymina uporablja le v zelo majhnih odmerkih.
English: Radiolabelling is a technique where a substance is labelled with a radioactive compound.
Slovenian: Radioaktivno označevanje je tehnika, pri kateri se snov označi z radioaktivno spojino.
English: 64Cu is a radioactive form of copper.
Slovenian: 64Cu je radioaktivna oblika bakra.
English: Radiolabelling of a medicine takes place outside the body in a laboratory setting.
Slovenian: Radioaktivno označevanje zdravila se opravi zunaj telesa, v laboratoriju.
English: Therefore, the CHMP decided that Cuprymina's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: CHMP je zaključil, da so koristi zdravila Cuprymina večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Cuprymina.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Cuprymina, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: Cuprymina itself is radioactive and so its use in radiolabelling may carry a risk of cancer and hereditary defects.
Slovenian: Zdravilo Cuprymina je radioaktivno, zato njegova uporaba pri radioaktivnem označevanju predstavlja tveganje za raka in dedne okvare.
English: What is the risk associated with Cuprymina?
Slovenian: Kakšna tveganja so povezana z zdravilom Cuprymina?
English: Cuprymina must not be given directly to any patient.
Slovenian: Zdravilo Cuprymina se ne sme dati bolniku neposredno.
English: Some of the scientific literature presented showed how radiolabelling with radioactive forms of Copper, including 64Cu, were used together with imaging techniques to detect the site and spread of tumours and how it could potentially be used to treat various types of cancer.
Slovenian: V delu predložene znanstvene literature je bila prikazana uporaba radioaktivnega označevanja z radioaktivnimi oblikami bakra, vključno s 64Cu, skupaj s slikovnimi tehnikami z namenom odkrivanja položaja tumorjev in njihovega razširjanja ter možnosti zdravljenja različnih vrst raka.
English: It must not be used in people who are hypersensitive (allergic) to copper (64Cu) chloride or any of the other ingredients.
Slovenian: Tega zdravila ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) bakrov (64Cu) klorid ali katero koli drugo sestavino zdravila.
English: Given the well-known risks of exposure to radiation through radiolabeling, the Committee decided that Cuprymina is only to be used if justified by the likely medical benefit.
Slovenian: Glede na dobro znana tveganja izpostavljanja sevanju pri radioaktivnem označevanju CHMP meni, da se sme zdravilo Cuprymina uporabljati le, kadar je to upravičeno na podlagi predvidenih kliničnih koristi.
English: Cuprymina is not used on its own but is used for radiolabelling other medicines.
Slovenian: Zdravilo Cuprymina se ne uporablja samostojno, ampak za radioaktivno označevanje drugih zdravil.
English: The radiolabelled medicine is then given to the patient according to the instructions in that medicine's summary of product characteristics (SmPC).
Slovenian: Nato bolnik prejme radioaktivno označeno zdravilo po navodilih iz povzetka glavnih značilnosti označenega zdravila (SmPC).
English: The company presented information from the scientific literature on the potential uses of Cuprymina.
Slovenian: Predlagatelj je predstavil podatke o možnih uporabah zdravila Cuprymina iz znanstvene literature.
English: Cuprymina is only to be used by specialists who have experience in radiolabelling.
Slovenian: Zdravilo Cuprymina smejo uporabljati le zdravniki specialisti, izkušeni na področju radioaktivnega označevanja.
English: The intended effect of the radiation will depend on the nature of the medicine that has been radiolabelled.
Slovenian: Želeni učinek sevanja je odvisen od narave zdravila, ki se radioaktivno označi.
English: Why has Cuprymina been approved?
Slovenian: Zakaj je bilo zdravilo Cuprymina odobreno?
English: The active substance in Cuprymina, copper (64Cu) chloride, is a radioactive compound that emits a type of radiation known as beta radiation.
Slovenian: Zdravilna učinkovina v zdravilu Cuprymina, bakrov (64Cu) klorid, je radioaktivna spojina, ki oddaja sevanje, imenovano beta sevanje.
English: Cuprymina is used to radiolabel medicines that have been specially developed for use with copper (64Cu) chloride.
Slovenian: Zdravilo Cuprymina se uporablja za radioaktivno označevanje zdravil, ki so bila posebej razvita za uporabo z bakrovim (64Cu) kloridom.
English: Once the substance is radiolabelled with Cuprymina, it then carries the radioactivity to where it is needed in the body.
Slovenian: Ko je snov radioaktivno označena z zdravilom Cuprymina, prenese radioaktivnost do ciljnega področja v telesu.
English: The information supplied by the company showed that Cuprymina can be used to radiolabel medicines with 64Cu, with potential utility for detecting of the sites and spread of tumours.
Slovenian: Podatki, ki jih je predložil predlagatelj, kažejo, da se zdravilo Cuprymina lahko uporabi za radioaktivno označevanje zdravil s 64Cu z možno uporabnostjo pri odkrivanju položaja tumorjev in njihovega razširjanja.
English: Medicines to be radiolabeled with Cuprymina can only be obtained with a prescription.
Slovenian: Izdaja zdravil, ki se radioaktivno označijo z zdravilom Cuprymina, je le na recept.
English: When a medicine is radiolabelled with Cuprymina, the medicine will carry the radiation to the particular site or type of cell in the body that is targeted by the medicine.
Slovenian: Z zdravilom Cuprymina radioaktivno označeno zdravilo bo preneslo sevanje do ciljnega mesta zdravila: določenega dela telesa ali določene vrste celic.
English: Cuprymina is a solution that contains the radioactive substance copper (64Cu) chloride.
Slovenian: Zdravilo Cuprymina je raztopina, ki vsebuje radioaktivno snov bakrov (64Cu) klorid.
English: More information on the restrictions on the use of medicines radiolabelled with Cuprymina will be found in their package leaflets.
Slovenian: Za več podatkov o omejitvah uporabe zdravil, radioaktivno označenih z zdravilom Cuprymina, glejte njihova navodila za uporabo.
English: How has Cuprymina been studied?
Slovenian: Kako je bilo zdravilo Cuprymina raziskano?
English: What is Cuprymina?
Slovenian: Kaj je zdravilo Cuprymina?
English: What is Cuprymina used for?
Slovenian: Za kaj se zdravilo Cuprymina uporablja?
English: How is Cuprymina used?
Slovenian: Kako se zdravilo Cuprymina uporablja?
English: The side effects with Cuprymina depend largely on the medicine it has been used to radiolabel and will be described in that medicine's package leaflet.
Slovenian: Neželeni učinki pri uporabi zdravila Cuprymina so odvisni predvsem od zdravila, ki je bilo radioaktivno označeno.
English: How does Cuprymina work?
Slovenian: Kako zdravilo Cuprymina deluje?
English: This takes around 30 minutes.
Slovenian: To traja približno 30 minut.
English: 96 to 144 weeks
Slovenian: 96 do 144 tednov
English: 52 weeks
Slovenian: 52 tednov
English: Read and follow the advice given in section 7.
Slovenian: Preberite in upoštevajte nasvete v poglavju 7.
English: The median duration was similar between the treatment groups.
Slovenian: Mediana trajanja je bila med skupinami zdravljenja podobna.
English: It should include the following elements:
Slovenian: Vsebovati mora naslednje elemente:
English: This stops nerves from working properly.
Slovenian: Zaradi tega živci prenehajo delovati pravilno.
English: It has not been determined whether these patients respond differently compared with younger patients.
Slovenian: Ni bilo ugotovljeno, ali se ti bolniki odzivajo drugače kot mlajši bolniki.
English: - if you have a serious infection, such as pneumonia.
Slovenian: - če imate resno okužbo, kot je pljučnica.
English: Efficacy in patients with highly active disease Highly active disease was defined as follows:
Slovenian: Učinkovitost pri bolnikih z zelo aktivno boleznijo Zelo aktivna bolezen je bila opredeljena kot sledi:
English: This is normal and will not affect your dose.
Slovenian: To je normalno in ne vpliva na odmerek.
English: You will hear the clicking sounds start.
Slovenian: Slišali boste, ko se bo začelo klikanje.
English: The incidence of the adverse reactions is expressed according to the following categories:
Slovenian: Incidenca neželenih učinkov je izražena po naslednjih kategorijah:
English: Following a recovery period of up to 12 weeks, there was evidence of reversibility.
Slovenian: Po do 12-tedenskem obdobju okrevanja so opazili dokaze reverzibilnosti.
English: - if you have ever had tuberculosis (also called TB) or live in a region where TB infections are common, you may be at greater risk of TB.
Slovenian: - če ste kadar koli imeli tuberkulozo (imenovano tudi TB) ali živite na območju, kjer so okužbe s TB pogoste, imate lahko večje tveganje za TB.
English: • The need to exercise caution regarding concomitant use of other hepatotoxic medications;
Slovenian: • potrebni previdnosti glede sočasne uporabe drugih hepatotoksičnih zdravil;